FORM	4
------	---

(Print or Type Responses)

-	Check this box if no
	longer subject to Section
	16. Form 4 or Form 5
	obligations may continue.
	See Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

SEC 1474 (9-02)

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Rep FRATTAROLI JOSEF	]	2. Issuer Name <b>and</b> Ticker or Trading Symbol Inhibikase Therapeutics, Inc. [IKT]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
3350 RIVERWOOD P	(First) ARKWAY SE, SUI	TTT 1000	3. Date of Earliest Transaction (Month/Day/Year) 12/22/2020						X Officer (give title below) Other (specify below) Chief Financial Officer		
ATLANTA, GA 30339	4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)		Table I	- Noi	n-Derivati	ve Securit	red, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year		(Instr. 8)		or Disposed of (D)		, í	(Instr. 3 and 4)	Ownership Indirect Form: Beneficial	
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock		12/28/2020		С		44,143	А	\$ 10	44,143	I	By Flagship Consulting, Inc.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	Price of	Date	Date Execution Date, if	Transaction Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Expiration Date (Month/Day/Year)		of Underlying Securities		Derivative Security (Instr. 5)	Securities	Ownership Form of Derivative	11. Nature of Indirect Beneficial Ownership
	Derivative Security			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following	Direct (D) or Indirect	
Stock Option (right to buy)	\$ 10	12/22/2020		А		100,000		<u>(1)</u>	12/22/2030	Common Stock	100,000	\$ 0	100,000	D	
Convertible Note	\$ 10	12/28/2020		С			\$ 441,431.52	12/28/2020	12/31/2021	Common Stock	44,143	\$ 0	0	Ι	By Flagship Consulting, Inc.

### **Reporting Owners**

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
FRATTAROLI JOSEPH 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA, GA 30339			Chief Financial Officer					

# Signatures



## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) One-third of the option will vest and become exercisable on 12/22/2021, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of the month beginning January 1, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.